This marks the 11th th country to which Avicanna has successfully completed the export of Aureus brand products in what represents a demonstration of the company’s capabilities, innovation and regulatory experience. This export also validates the emergence of the global cannabinoid sector based on the quality, traceability and sustainability offered by Avicanna’s Aureus products.
With a projected total market size of approximately US $ 9 billion by 2025 1 , Brazil is expected to be one of the largest and largest cannabis markets in the world and the largest in Latin America, especially for medicinal cannabis products. Cannabis extracts will be used in the production of various products that will be registered and marketed in Brazil through RDC 327/19 which regulates the manufacture, registration, import and dispensing of cannabis products.
Lucas Nosiglia, President of Avicanna LATAM, commented: “This export represents a key milestone for our team and a validation of our capabilities as we continue to lead the way with our products and we have now entered our 11 th country with the Aureus brand. Exports to Brazil also confirm the regulatory route and act as a proof of concept in the largest market in South America, where we aim to establish long-term supply relationships with our Brazilian pharmaceutical partners.
To the knowledge of the company, it carries out its operations in accordance with all the laws applicable to the jurisdictions in which it operates.
1 Source: Passport, Euromonitor International, Cannabis in Latin America, July 2021
About Aureus ™
Avicanna’s supply chain business units are headquartered in Santa Marta, Colombia and are primarily dedicated to providing a consistent source of cannabinoid raw materials for Avicanna’s current commercial products and pharmaceutical pipelines for the global market.
In addition, under the Aureus ™ brand, standardized cannabis extracts and feminized seeds are available to crop partners, cosmetics and pharmacists around the world. Aureus brand products are grown, extracted and manufactured by Avicanna’s subsidiaries in Colombia, where they benefit from optimal environmental conditions to produce active cannabinoid pharmaceutical ingredients in an economical and sustainable way and include a range of CBD extracts. , THC and rare cannabinoids such as CBG. Avicanna’s supply chain business also benefits from federally regulated legislation in Colombia, where the company is well positioned to be a global supplier of less competitive psychoactive extracts, including crude oil CBD and THC, to meet the growing world demand.
Avicanna is a vertically diversified and integrated Canadian biopharmaceutical company focused on the research, development and commercialization of herbal cannabinoid-based products for the global consumer, medical and pharmaceutical market segments.
Avicanna is a consolidated leader in cannabinoid research and development, leading primarily at its R&D headquarters at the Johnson & Johnson Innovation Center, JLABS @ Toronto, Canada and in collaboration with Canadian medical and academic institutions. In addition to its development of pharmaceutical pipelines, Avicanna’s team of experts has developed and marketed several industry-leading product lines, including:
- RHO Phyto ™: an advanced line of medical cannabis products containing different proportions of CBD and THC currently available across Canada through medical channels in collaboration with Medical Cannabis for Shoppers ™, a subsidiary of Shoppers Drug Mart, and in adult use channels through provincial retailers. RHO Phyto is the first medical form of “Cannabis 2.0” advanced products, containing oils, aerosols, capsules, creams and gels, all developed with scientific rigor, manufactured under GMP standards and supported by preclinical data; i,
- Pure H&W ™: an advanced and clinically proven line of functional dermocosmetic products for CBD consumers currently available across Canada through medical channels in collaboration with Medical Cannabis for Shoppers ™, a subsidiary of Shoppers Drug Mart, in adult use channels through provincial retailers in Canada and nationwide throughout Colombia.
With ongoing clinical studies on its derma-cosmetic products (Pura H&W), medicinal cannabis (RHO Phyto) and a number of pharmaceuticals, Avicanna’s dedication to investigating the important role that cannabinoids play in an increasing scope Wide range of products has been the core of the company’s vision since its inception. In addition, Avicanna’s commitment to education is demonstrated through its annual medical symposium, the Avicanna Academy educational platform, and the My Cannabis Clinic patient program through its subsidiary company.
Avicanna manages its own supply chain, including cultivation and extraction, through its two wholly owned subsidiaries, Sativa Nativa SAS and Santa Marta Golden Hemp SAS, both located in Santa Marta, Colombia. Through these subsidiaries on a sustainable, economic, and industrial scale, Avicanna grows, processes, and markets a variety of dominant cannabis and hemp crops on CBD, CBG, THC, and other cannabinoids for use as active pharmaceutical ingredients. Avicanna’s Avesta Genetica program specializes in the development and optimization of rare cultivars for commercial production along with feminized seeds for global export. In June 2020, Avicanna made history with a shipment of hemp seeds to the United States of America by conducting the first export of hemp seeds from Colombia.
FONT Avicanna Inc.
For more information about Avicanna, visit www.Avicanna.com, call 1-647-243-5283 or contact Iryna Zheliasko by email at [email protected]
The company posts updates via videos from the company’s official YouTube channel https://www.youtube.com/channel/UC5yBclNIsNf7VrE34iwt8OA .
Caution note on information and forecast statements
This press release contains “forward-looking information” within the meaning of applicable securities laws. The forward-looking information contained in this press release can be identified by the use of words such as: “may”, “could”, “could”, “will”, “likely”, “expect”, “anticipate”, “believe ”,“ Intent ”,“ Plan ”,“ Forecast ”,“ Project ”,“ Estimate ”,“ Outlook ”and other similar expressions, and includes statements about SMGH’s ability to complete additional exports of cannabis extracts to Brazil, SMGH’s ability to continue growing, extracting and manufacturing cannabis extracts and SMGH’s ability to supply pharmaceutical and cosmetic companies with cannabinoids (including rare cannabinoids), as well as supplying traditionalized and feminized seed companies worldwide. Prospective information is not a guarantee of future performance and is based on a series of estimates and assumptions about management in the light of experience and management’s perception of trends, current conditions and expected developments, as well as other relevant factors in the circumstances, including assumptions about current and future market conditions, the current and future regulatory environment; and the availability of licenses, approvals, and permits.
While the Company believes that the expectations and assumptions on which this forward-looking information is based are reasonable, the forward-looking information should not be unduly relied upon because the Company cannot provide warranties that prove to be correct. Actual results and developments may differ materially from those contemplated in these statements. Prospective information is subject to various risks and uncertainties that may cause actual events or results to differ materially from those projected in the forward-looking information. These risks and uncertainties include, but are not limited to, current and future market conditions, including the market price of the Company’s common shares, and the risk factors set forth in the company’s annual information form dated 15 April 2020, and final short brochure dated November 27, 2020, presented to Canadian securities regulators and available under the company profile at SEDAR a www.sedar.com .
Statements in this press release are made as of the date of this release. The Company disclaims any intention or obligation to update any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.
Sometimes we include links to online retail stores. If you click on one and make a purchase we may receive a small commission.